Location Directory

Clinical trials in Cincinnati, Ohio

This page shows live ClinicalTrials.gov search results for Cincinnati, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

10564

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Asthma
Interventions: QAW039, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 55
States / cities: Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 49 more

Conditions: Aortic Valve Insufficiency, Aortic Valve Stenosis
Interventions: SAPIEN X4/X4S THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2039
U.S. locations: 34
States / cities: Newport Beach, California • San Francisco, California • Stanford, California + 26 more

Conditions: Narcolepsy Type 1
Interventions: ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Brandon, Florida • Miami, Florida • Winter Park, Florida + 12 more

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 533
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 340 more

Conditions: Narcolepsy Type 2
Interventions: ALKS 2680 Dose 1, ALKS 2680 Dose 2, ALKS 2680 Dose 3, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Cullman, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more

Conditions: PIK3CA-related Overgrowth Spectrum (PROS)
Interventions: Alpelisib, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 0 Days to 100 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • St Louis, Missouri + 7 more

Conditions: Post Operative Atrial Fibrillation, Atrial Fibrillation, Postoperative
Interventions: Isolator® Synergy™ EnCompass® Ablation System and AtriClip® LAA Exclusion System; Device
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 33
States / cities: Scottsdale, Arizona • Jonesboro, Arkansas • San Diego, California + 27 more

Conditions: Obesity, Overweight, Obstructive Sleep Apnoea
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Gilbert, Arizona • Bradenton, Florida • Naples, Florida + 16 more

Conditions: Idiopathic Scoliosis
Interventions: Methadone based ERAS, Non-methadone based group; Drug
Lead sponsor: Senthil Sadhasivam; Other
Eligibility: 10 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Indianapolis, Indiana • Cincinnati, Ohio • Pittsburgh, Pennsylvania + 1 more

Conditions: Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions: RO7198457 intravenous (IV), Observational group (no intervention); Drug · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 15
States / cities: Greenbrae, California • Indianapolis, Indiana • Minneapolis, Minnesota + 12 more

Conditions: Primary Biliary Cholangitis
Interventions: K-808 (Dose A), K-808 (Dose B), Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 21
States / cities: Tucson, Arizona • Coronado, California • Los Angeles, California + 18 more

Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Interventions: Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY; Combination Product · Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 32
States / cities: Stamford, Connecticut • Miami, Florida • Atlanta, Georgia + 20 more

Clinical trials in Cincinnati, Ohio

Filter and sort this location

Live official records

Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.

ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

BoxX-NoAF Clinical Trial

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Evaluation of Analgesia for Spine Fusion Elective Surgery in Children

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer